Tryptamine Studies 2025/2026: Current Pharmacology Data

Tryptamine pharmacology research has moved fast in 2025-2026. Glatfelter et al. (2023) keep generating derivative studies with expanded receptor binding profiles for 4-substituted tryptamines. Multiple Phase III psilocybin trials have reached completion. Non-hallucinogenic psychoplastogens entered Phase II testing. And the EUDA (European Union Drugs Agency) published its first formal risk assessments of novel tryptamines. Here's the data that matters most for 4-Pro-MET and its chemical relatives.

The single most relevant paper? Glatfelter et al. (2023) in ACS Pharmacology & Translational Science. They characterized receptor binding profiles and mouse behavioral data for multiple 4-substituted tryptamines, including 4-PrO-DMT – the closest structural analogue to 4-Pro-MET with published data. The numbers: 5-HT2A Ki of 336 nM for 4-PrO-DMT, functional EC50 of 3-93 nM with 93-104% efficacy, head-twitch response ED50 of 0.31 mg/kg, and a kappa-opioid receptor affinity (Ki = 4,745 nM) that none of the other tested compounds shared. That last finding caught attention.

On 4-HO-MET itself – the metabolite 4-Pro-MET converts into – the literature is slim but real. In vitro metabolic studies identified 12 metabolites via human liver microsomes (Forensic Science International, 2018). A non-fatal intoxication case documented plasma concentration of 193 ng/mL (Journal of Analytical Toxicology, 2021). And a Swedish phenomenological study of 4-HO-MET use goes back to 2011 (PubMed: 22111404).

No clinical trials exist for 4-Pro-MET. But the broader tryptamine landscape gives useful context. As of early 2026, over 15 Phase II/III psilocybin trials are active or completed. COMPASS Pathways' Phase IIb trial for treatment-resistant depression (n=233), published in the New England Journal of Medicine, showed significant efficacy at 25 mg dose. Usona Institute's Phase II trial for major depressive disorder landed similar results. The money followed: the global psychedelic therapy market is projected to reach $10+ billion by 2030.

One thing stands out, though. Every current clinical program uses psilocybin or synthetic psilocin – not novel tryptamines like 4-Pro-MET. Getting a new tryptamine through independent Phase I-III development would cost $50-100+ million and take 5-10+ years. That's a high bar.